ArriVent BioPharma, Inc. AVBP Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense Product With Specified Ingredient by Product | ||||||
| Drug Firmonertinib Favour | $726K+177% | $397K+46.0% | $471K-2.2% | $315K-56.7% | $262K-75.2% | |
| Drug Firmonertinib Further | $8.98M-21.5% | $9.84M-19.8% | $9.39M-38.1% | $10.38M-38.1% | $11.44M-34.9% | |
| Drug Firmonertinib Furvent | $48.43M+37.3% | $48.74M+42.8% | $42.93M+39.7% | $38.07M+34.8% | $35.28M+27.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ArriVent BioPharma, Inc. break its business down?
- ArriVent BioPharma, Inc. (AVBP) reports research and development expense product with specified ingredient by product across 3 parts — Drug Firmonertinib Favour, Drug Firmonertinib Further and Drug Firmonertinib Furvent. Each is extracted from the segment footnotes and tracked over time.
- Where does ArriVent BioPharma, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ArriVent BioPharma, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.